Camp4 Therapeutics annual shares outstanding
2022
2023
2024
2025
Camp4 Therapeutics Shares Outstanding History (CAMP)
Camp4 Therapeutics reported 51.9M shares outstanding at the end of fiscal 2025.
View full Camp4 Therapeutics company overviewCamp4 Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 51.9M | 31.8M | +157.64% |
| 2024 | 2024-12-31 | 20.1M | 19.7M | +4272.68% |
| 2023 | 2023-12-31 | 460,704 | −19.0M | −97.64% |
| 2022 | 2022-12-31 | 19.5M | — | — |
Camp4 Therapeutics quarterly shares outstanding
Q4.23
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 51.9M | 31.8M | +157.56% |
| Q1 2026 | 2026-03-31 | 51.9M | 31.8M | +157.61% |
| Q4 2025 | 2025-12-31 | 51.9M | 31.8M | +157.64% |
| Q3 2025 | 2025-09-30 | 46.9M | 45.9M | +4560.38% |
| Q2 2025 | 2025-06-30 | 20.2M | — | — |
| Q1 2025 | 2025-03-31 | 20.2M | — | — |
| Q4 2024 | 2024-12-31 | 20.1M | 19.7M | +4272.68% |
| Q3 2024 | 2024-09-30 | 1.0M | — | — |
| Q4 2023 | 2023-12-31 | 460,704 | — | — |
Camp4 Therapeutics shares outstanding trends
Between the periods ended 2022-12-31 and 2025-12-31, Camp4 Therapeutics's shares outstanding moved from 19.5M to 51.9M, a change of 32.4M. The latest reported quarter, Q2 2026, shows 51.9M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Camp4 Therapeutics source filings ↗Community posts
CAMP4 receives UK authorization for its first SYNGAP1 clinical study
CAMP4 Therapeutics ($CAMP) received UK authorization to include sites in its global Phase 1/2 study of CMP002, an investigational treatment for SYNGAP1-related disorder. The decision follows earlier clearances in Australia and Argentina, wh ...